This website uses cookies primarily for visitor analytics. Certain pages will ask you to fill in contact details to receive additional information. On these pages you have the option of having the site log your details for future visits. Indicating you want the site to remember your details will place a cookie on your device. To view our full cookie policy, please click here. You can also view it at any time by going to our Contact Us page.

Cheaper Covid-19 test more efficient than PCR in detecting alpha variant

06 May 2022

A new point-of-care Covid test has proven successful in differentiating the alpha variant from previous strains.

(Image: Shutterstock)
(Image: Shutterstock)

The new test builds on researchers at the University of Illinois Urbana-Champaign’s previous developments, which allowed samples to bypass the laboratory – first using nasopharyngeal swabs, then with saliva samples. 

The point-of-care amplification and testing process, called LAMP, is more efficient than PCR because it does not require expensive thermal cycling machines. The researchers said the assay does not need RNA extraction and purification steps, similar to the Illinois saliva test.

“Our study shows that it is possible to test for variants of the same coronavirus strain in a single point-of-care test that takes 30 minutes using a portable handheld device,” Bashir said. 

“The new test is scalable to suit future pandemics, COVID-19 or otherwise, and could be used at home or other settings.”         
The updated process takes advantage of a genetic phenomenon called S-gene target failure – which is present in the alpha variant but not in the SARS-CoV-2 virus early strains – to differentiate between the two alpha variants, the researchers said.

“The new omicron variant also exhibits S-gene target failure and could be tested for by adapting the approach developed in this study,” Valera said.

During the new testing process, specially selected genetic primers are placed onto additively manufactured cartridges and dried before adding the patient samples. The chosen primers are set against the S-gene and are specific for detecting the S-gene target failure against 69-70 deletion in the alpha variant, the study reports.

The study confirmed the device’s effectiveness by testing 38 clinical saliva samples, including 20 samples positive for alpha variant.

The researchers said they would like to refine their method to test up to five different viruses, viral strains and variants in a single test, compatible with a nasal swab and saliva mediums.

Print this page | E-mail this page